Sign in
TerminatedNo phase

Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Status
Terminated
People taking part
3 people enrolled
Started
17 Nov 2022
Ended
5 Nov 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Simulated Online Adaptive Planning
  • Stereotactic MRI-guided adaptive radiotherapy-SMART
Record updated
10 November 2025
Why it stopped
\<75 % participation

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Primary lung cancer or lung metastasis from another primary
  • Central tumors ≤ 2 cm from any mediastinal critical structure (proximal bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve
  • Age ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent
  • Primary lung cancer or lung metastasis from another primary
  • Central tumors ≤ 2 cm from any mediastinal critical structure (proximal bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve
  • Age ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent
  • Determined by two thoracic radiation oncologists to require > 10-15 fraction regimens if treated with CT-based, non-adaptive radiation therapy

Who cannot take part

  • Women who are pregnant. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately; Stage 2:
  • Women who are pregnant. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
  • Inability to tolerate MR imaging (Ie. history of claustrophobia)
  • Inability to tolerate MR imaging (Ie. history of claustrophobia)
  • Contraindications to MR imaging (e.g. implanted metallic prostheses, defibrillators, stimulators, pacemakers, or neurotransmitters) per institutional policy on management of patients with internal and external medical devices
  • Contraindications to MR imaging (e.g. implanted metallic prostheses, defibrillators, stimulators, pacemakers, or neurotransmitters) per institutional policy on management of patients with internal and external medical devices

Other criteria

  • Stage I:

Where in United States

  • M D Anderson Cancer CenterHouston, United States

About the trial

What the trial wants to find out

To learn if using MRI (magnetic resonance imaging) to guide radiation therapy can help to control central lung cancer. The results of the MRI-guided radiation therapy will be compared to conventional radiation therapy (guided by CT scans) during this study.

The 2 groups in the trial

  • Stage I-(Simulated Online Adaptive Planning)Treatment being tested

    Participants will receive treatment with the conventional CT-based radiation therapy and receive additional MRI scans.

    Treatment: Simulated Online Adaptive Planning

  • Stage II (Stereotactic MRI-guided adaptive radiotherapy-SMART)Treatment being tested

    Participants will receive treatment with the investigational MRI-guided radiation therapy.

    Treatment: Stereotactic MRI-guided adaptive radiotherapy-SMART

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
10 November 2025